Pharminent

How Startups Are Trying To Overcome India’s Healthcare Challenges

As Health Care Industry is projected to grow by 17% (compounded annual growth rate) by 2020; startups are attempting to overcome problems such as poor health infrastructure, low levels of insurance, and rural vs urban disparity that are plaguing health services in India. https://www.forbes.com/sites/krnkashyap/2017/09/25/how-startups-are-trying-to-overcome-indias-healthcare-challenges/

Filed under: Emerging Markets

Trovagene Announces Agreement with Novogene for NextCollect™ in China

SAN DIEGO, July 12, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), today announced that they have entered into an agreement with Novogene Co. Ltd., a leading global provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and the largest sequ… http://www.prnewswire.com/news-releases/trovagene-announces-agreement-with-novogene-for-nextcollect-in-china-300486641.html

Filed under: Emerging Markets

China FDA changes will speed up approval process, says CRO

Proposed changes to drug, medical device and clinical testing regulations provide stimulus for conducting trials in China, says CRO George Clinical. http://www.outsourcing-pharma.com/Clinical-Development/China-FDA-changes-will-speed-up-approval-process-says-CRO

Filed under: Emerging Markets

India’s drugmakers need more time to meet international standards: industry group

MUMBAI (Reuters) – India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

http://www.reuters.com/article/us-india-pharmaceuticals-regulation-idUSKCN18D1CU

Filed under: Emerging Markets

Generic consistency evaluation in China: the coming paradigm shift in drug pricing and patent cliff

China is one of the largest generic drug markets in the world. As part of the drug approval reform, the ongoing generic consistency evaluation (GCE) is likely to have significant, long-lasting impacts on the market landscape, drug pricing and generic…By: Allen & Overy LLP http://www.jdsupra.com/legalnews/generic-consistency-evaluation-in-china-27347/

Filed under: Emerging Markets

New guidelines to make China a more drug-friendly market

CFDA announces draft guidelines that would allow Phase I trials in China to encourage simultaneous development alongside global trials. http://www.biopharmadive.com/news/china-drug-trials-manufacturing-generics-cfda/439487/

Filed under: Emerging Markets

AZ gets rapid approval in China for Tagrisso

Lung cancer treatment becomes first medicine to pass through the country’s Priority Review pathway http://www.pmlive.com/pharma_news/az_gets_rapid_approval_in_china_for_tagrisso_1190097

Filed under: Emerging Markets

Drug prices set to increase on ‘essential medicines’ list in India

The annual review of drug prices will see the price of drugs, on the National List of Essential Medicines, increase by just under 2%. The Indian Government has strict measures to control the pricing of drug prices, something that the Indian pharmaceutical industry has found increasingly difficult, with the latest price increases set to bring medicines in-line with inflation.
read more http://www.pharmafile.com/news/513643/drug-prices-set-increase-essential-medicines-list-india

Filed under: Emerging Markets

China considers ways to speed up time to market for imported drugs

BEIJING (Reuters) – China is considering taking measures that will shorten the time to market for approved imported drugs in an effort to ease a shortage of such medicines, according to the China Food and Drug Administration (CFDA).

http://www.reuters.com/article/us-china-pharmaceuticals-idUSKBN16R0DZ

Filed under: Emerging Markets

China releases update of key reimbursable drug list

SHANGHAI (Reuters) – China has released the updated 2017 list of medicines covered by its basic medical insurance schemes, the Ministry of Human Resources and Social Security said in a statement on Thursday.

http://www.reuters.com/article/us-china-pharmaceuticals-idUSKBN1620D7

Filed under: Emerging Markets

China’s State Council Announces Major Policies to Reform the Pharmaceutical Industry

China will launch further reforms in the pharmaceutical sector as part of the healthcare reform initiatives announced by the State Council in its February 9, 2017 Circular on Several Opinions Concerning Further Reforms of the Policies Governing Drug…By: Ropes & Gray LLP http://www.jdsupra.com/legalnews/china-s-state-council-announces-major-42104/

Filed under: Emerging Markets

‘Make in India’ strategy to kickstart domestic biomanufacturing, Biocon

A lack of investment and government support has stunted biomanufacturing in India, but Biocon says this will change through the country’s ‘Make in India’ programme. http://www.biopharma-reporter.com/Markets-Regulations/Make-in-India-strategy-to-kickstart-biomanufacturing-Biocon

Filed under: Emerging Markets

Sanofi and JHL Biotech Announce Strategic Biologics Alliance in China

[PR Newswire] – Under the agreement, Sanofi will invest US$80 million in newly issued JHL shares at NT$90 per share. In addition, Sanofi will make an upfront payment of US$21 million to acquire exclusive rights for the proposed biosimilar of Rituximab and options to certain JHL pipeline products. JHL will lead the development, registration, and manufacturing activities while Sanofi will lead commercialization efforts in China. http://finance.yahoo.com/news/sanofi-jhl-biotech-announce-strategic-000000327.html

Filed under: Emerging Markets

The Incredible Potential And Challenges Facing China’s Online Healthcare System

China’s healthcare system has its share of peculiar challenges. But, what we are beginning to see is that these challenges are also giving rise to specific innovations by domestic Chinese entrepreneurs. http://www.forbes.com/sites/benjaminshobert/2016/11/29/the-incredible-potential-and-challenges-facing-chinas-online-healthcare-system/

Filed under: Emerging Markets

Henry Ford Health System Licenses Healthcare Technology To New Specialty Care Hospital In India

DETROIT, Sept. 29, 2016 /PRNewswire/ — Henry Ford Health System, headquartered in Detroit, Michigan, has licensed its state of the art technology for the development of a new specialty care hospital in southern India. Officials from Pearl Human Care Private Limited, based in India’s… http://www.prnewswire.com/news-releases/henry-ford-health-system-licenses-healthcare-technology-to-new-specialty-care-hospital-in-india-300336297.html

Filed under: Emerging Markets

Dr. Reddy’s expands collaboration with Amgen in India

Dr. Reddy’s Laboratories has expanded its strategic collaboration with Amgen to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis. http://contractservices.pharmaceutical-business-review.com/news/dr-reddys-expands-collaboration-with-amgen-in-india-190916-5008636

Filed under: Emerging Markets

Jacobs joins GE Healthcare as developer of Pfizer’s China mAb plant

Jacobs Engineering Group has been contracted to collaborate with GE Healthcare on the development of Pfizer’s $350m monoclonal antibody manufacturing centre in Hangzhou, China. http://mobile.biopharma-reporter.com/Downstream-Processing/Pfizer-China-single-use-plant-collaboration-between-Jacobs-and-GE

Filed under: Emerging Markets

In China, IBM Watson To Aid 12,000 Daily Cancer Diagnoses

IBM is bringing its Watson artificial intelligence system to China through a cancer treatment partnership with Hangzhou CognitiveCare, which will work with hospitals across China to improve oncology services and speed diagnosis. http://www.forbes.com/sites/brucejapsen/2016/08/11/in-china-ibm-watson-to-aid-12000-daily-cancer-diagnoses/

Filed under: Emerging Markets

Plenty of room for healthcare insurance growth in China: EY

http://www.fiercepharma.com/pharma-asia/plenty-room-for-healthcare-insurance-growth-china-ey

Filed under: Emerging Markets

India to rewrite 75-year old drug laws with an eye on business, biologics and devices

India has withdrawn a proposed amendment to its drug laws after deciding a more extensive rewrite is needed to allow the effective regulation of biologics, regenerative medicines and clinical trials. http://www.in-pharmatechnologist.com/Regulatory-Safety/India-to-rewrite-75-year-old-drug-laws-with-an-eye-on-business-biologics-and-devices

Filed under: Emerging Markets

Categories